BRAF and melanoma: For BRAF-mutated melanomas, both combined BRAF and MEK inhibition and anti-PD-1 are considered viable options, as there is no comparative data (yet) to select either drug in stage III-IV completely-resected melanoma patients, so at the moment the treatment is selected by the clinician on the basis of each individual patient’s characteristic.